J Cancer 2019; 10(20):4939-4946. doi:10.7150/jca.27616 This issue
1. Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, 310022, P.R. China
2. Department of Oncology, Wuxi Hospital of traditional Chinese Medicine, Wuxi, 214071, P.R. China.
3. Department of Gastroenterology, Wuxi People's Hospital, Affiliated to Nanjing Medical University, Wuxi, 214023, P.R. China.
4. Department of Oncology, Wuxi People's Hospital, Affiliated to Nanjing Medical University, Wuxi, 214023, P.R. China.
Objective: The lack of effective therapeutic targets poses a leading challenge to prolong survival and improve the quality of life for pancreatic cancer patients. Proteasome 26S subunit ATPase 2 (PSMC2), a recently discovered gene, has been implicated in certain human carcinogenesis. However, limited data is available concerning the functional significance of PSMC2 in cancer cell growth, and whether it plays a role in pancreatic carcinogenesis remains unknown.
Materials and Methods: Quantitative RT-PCR (qRT-PCR) was performed to assess mRNA expression levels of PSMC2 in different pancreatic cancer cell lines. Knockdown of PSMC2 was achieved by using short hairpin RNA (shRNA). The effects of PSMC2 silencing on pancreatic cancer cell proliferation and apoptosis were evaluated by the MTT cell proliferation assay, Celigoassays, Annexin V fluorescence-activated cell sorting (FACS) assay and Caspase-3/7 array.
Results: High expression of PSMC2 was detected in three pancreatic cancer cell lines (SW1990, PANC-1, and AsPC-1). Knockdown of PSMC2 in SW1990 cells inhibited proliferation and enhanced apoptosis.
Conclusions: Our primary study suggests that PSMC2 might be involved in the progression of pancreatic cancer and may serve as a potential therapeutic target.
Keywords: pancreatic cancer, PSMC2, the 26S proteasome, proliferation, apoptosis